arrow
R

Robert I. Haddad

Harvard University
H指数:107
被引数:7.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Head and Neck Cancers, Version 2.2025 Featured Updates to the NCCN Guidelines

头颈癌,版本2.2025:NCCN指南特色更新

2025-02-012
PRE
Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma
2024-10-220
OAAI
IMvoke010: A phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN)
2024-04-053
PRE
Biomarker benchmarking across ancestral populations

跨祖先人群的生物标志物基准

2023-12-010
PRE
INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)
2023-10-016
OA
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer
2023-09-2925
OA
Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial
2023-06-0116
OAAI
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
2023-03-0161
OA
Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer
2022-12-0133
OA
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
2022-08-0115
OAAI
Thyroid Carcinoma, Version 2.2022
2022-08-01219
OA